Apogee Therapeutics (APGE) Projected to Release Quarterly Earnings on Monday

Apogee Therapeutics (NASDAQ:APGE) is anticipated to issue its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to post earnings of ($1.07) per share and revenue of $10.00 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 9:30 AM ET.

Apogee Therapeutics (NASDAQ:APGE) last posted its earnings results on Monday, May 11th. The company reported ($1.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.01. On average, analysts expect Apogee Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Apogee Therapeutics Stock Performance

Shares of APGE stock opened at $134.09 on Monday. Apogee Therapeutics has a 52 week low of $34.34 and a 52 week high of $134.46. The company has a market capitalization of $8.30 billion, a price-to-earnings ratio of -30.97 and a beta of 0.32. The company has a 50-day simple moving average of $113.95 and a 200 day simple moving average of $90.07.

Analyst Upgrades and Downgrades

APGE has been the subject of several research reports. Truist Financial cut their price objective on shares of Apogee Therapeutics from $83.00 to $81.00 and set a “hold” rating for the company in a research report on Wednesday, May 27th. Canaccord Genuity Group downgraded Apogee Therapeutics from a “buy” rating to a “hold” rating and upped their target price for the company from $130.00 to $135.11 in a research report on Monday, June 22nd. Rothschild & Co Redburn began coverage on Apogee Therapeutics in a research note on Friday, May 1st. They set a “buy” rating and a $140.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Apogee Therapeutics in a report on Friday, July 17th. Finally, UBS Group lowered Apogee Therapeutics from a “buy” rating to a “neutral” rating and upped their price objective for the company from $100.00 to $135.11 in a report on Tuesday, June 23rd. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $121.25.

Insider Activity

In other Apogee Therapeutics news, CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $133.63, for a total value of $2,672,600.00. Following the completion of the sale, the chief executive officer owned 995,987 shares of the company’s stock, valued at $133,093,742.81. The trade was a 1.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Carl Dambkowski sold 5,500 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $132.74, for a total transaction of $730,070.00. Following the transaction, the insider owned 177,873 shares in the company, valued at approximately $23,610,862.02. The trade was a 3.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 182,900 shares of company stock valued at $21,711,585 in the last quarter. Corporate insiders own 24.30% of the company’s stock.

Institutional Investors Weigh In On Apogee Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Mariner LLC raised its holdings in Apogee Therapeutics by 54.9% in the 4th quarter. Mariner LLC now owns 9,101 shares of the company’s stock valued at $687,000 after acquiring an additional 3,224 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in shares of Apogee Therapeutics by 2.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 7,151 shares of the company’s stock valued at $540,000 after acquiring an additional 152 shares during the period. Fox Run Management L.L.C. acquired a new stake in shares of Apogee Therapeutics during the 4th quarter worth $481,000. Creative Planning acquired a new stake in shares of Apogee Therapeutics during the 2nd quarter worth $392,000. Finally, Public Employees Retirement Association of Colorado acquired a new stake in shares of Apogee Therapeutics during the 4th quarter worth $371,000. 79.04% of the stock is currently owned by institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.